Zealand Pharma on Thursday reported a significant surge in revenue and profit for the first nine months of 2025, driven by its recent partnership with Roche, while also announcing it has paused development of its experimental obesity drug, dapiglutide.
The Danish biotechnology company posted revenue of 9.15 billion Danish kroner for the period ended Sept. 30, up from 54 million Danish kroner a year earlier.
Its operating result swung to a profit of 7.67 billion Danish kroner from a loss of 873 million Danish kroner in the same period last year, the company said.
Zealand Pharma said the development of dapiglutide was paused as part of an active portfolio management strategy to focus investments on programs with the greatest potential.
As a result of this decision, the company narrowed its forecast for 2025 net operating expenses to between 2.0 billion and 2.3 billion Danish kroner.
“I am highly encouraged by the strong execution across our clinical programs and the momentum behind our partnership with Roche,” said Adam Steensberg, President and Chief Executive Officer at Zealand Pharma.
The company highlighted continued progress in its key obesity drug candidates, petrelintide, which is being co-developed with Roche, and survodutide, with key trial data for both expected in the first half of 2026.
More from this issuer
Related coverage
Zealand Pharma's revenue and profit soared in the first half of 2025, a direct result of a major partnership with Roche to develop its new weight-loss drug candidate, petrelintide.
Zealand Pharma on Wednesday reported positive results from a mid-stage study of its experimental obesity drug, dapiglutide, showing an average body weight reduction of 11.6% over 28 weeks.